Search Results

You are looking at 51 - 60 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

to improve the quality and effectiveness of care provided to patients with cancer.” New Therapies for Metastatic Disease Addressed in Updated NCCN Guidelines for Breast Cancer Women with metastatic breast cancer have expanded treatment options

Full access

Mary Lou Smith and Cynthia Chauhan

, advocates review recruitment issues for TBCRC trials and study issues around tissue collection and assess the role of clinical trials in the care of patients with metastatic breast cancer. They are active, voting members of the scientific working groups. As

Full access

Cesar A. Santa-Maria and Rita Nanda

therapy for metastatic breast cancer had an ORR of <8%. The phase IB JAVELIN study investigated avelumab, an anti–PD-L1 antibody, in various breast cancer subtypes. Avelumab monotherapy was associated with an ORR of 5.2% in the TNBC subgroup (n=58), which

Full access

.2007.0068 Counterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancer Cianfrocca Mary DO Gradishar William J. MD 09 2007 5 5 8 8 771 771 773 773 0050771 10.6004/jnccn.2007.0069 Breast Risk

Full access

David M. Dunning and Thomas A. Paivanas

Oncol 1995 ; 13 : 1860 – 1870 . 11. Goldenberg MM . Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer . Clin Ther 1999 ; 21 : 309 – 318 . 12

Full access

-Positive Metastatic Breast Cancer Vontela Namratha MD Koduri Vamsi MD Schwartzberg Lee S. MD Vidal Gregory A. MD, PhD 3 2017 15 15 3 3 284 284 287 287 0150284 10.6004/jnccn.2017.0029 NCCN Guidelines Insights: Chronic Lymphocytic Leukemia

Full access

Sharon H. Giordano, Anthony D. Elias and William J. Gradishar

the response rate and improved median PFS from 4.2 to 7.0 months compared with standard therapy (HR, 0.58; P <.001). 7 Similar data now exist for talazoparib. Olaparib is approved for previously treated metastatic breast cancer with germline BRCA

Full access

Jonas A. de Souza, Mark J. Ratain and A. Mark Fendrick

prescribed for metastatic breast cancer (10 mg/kg every 2 weeks), for which it initially provided a debatable median progression-free survival benefit of 5.5 months 18 , 19 (HR for progression, 0.48; 95% CI, 0.39-0.61; P < .0001) that has not been

Full access

Catherine Larkin

continuing to recommend bevacizumab in metastatic breast cancer shows “logical consistency” because many approved drugs have also failed to show benefits in survival or quality of life. The panel discussed bevacizumab 3 times in the 4 to 5 months leading up

Full access

resistance to CDK4 & 6 inhibitor treatment in metastatic breast cancer.” “We are excited to support NCCN to further understand the mechanisms of resistance to CDK4 & 6 inhibitors in advanced breast cancer, which is a central and critically important issue